<DOC>
	<DOCNO>NCT02191137</DOCNO>
	<brief_summary>The MOTION study prospective , Phase IV study , enrol 61 patient Pulmonary Arterial Hypertension ( PAH ) . The study design explore patient-reported outcome PAH subject active treatment living United States . In addition , study explore use new telemetric technology ( Accelerator band ) evaluate technology correlate improvement 6 Minute Walking Distance 6MWD patient PAH</brief_summary>
	<brief_title>Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not Active Treatment ( MOTION )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Male female patient , 18 80 year age Visit 0 Women childbearing potential must negative pretreatment pregnancy test , negative monthly pregnancy test , must use reliable method contraception accord Risk Evaluation Mitigation Strategies ( REMS ) guidance Symptomatic pulmonary arterial hypertension , World Health Organization Group 1 pulmonary vascular resistance ( PVR ) &gt; 300 dyn*sec*cm5 , mean pulmonary artery pressure ( PAP mean ) ≥25 mmHg , pulmonary capillary wedge pressure ( PCWP ) ≤15 mmHg assess right heart catheterization within 6 month prior Screening ( Visit 0 ) PAH follow type : Idiopathic ( IPAH ) Familial ( FPAH ) Associated PAH ( APAH ) due : Connective tissue disease Congenital heart disease , patient underwent surgical repair one year enrollment Anorexigen amphetamine use Portal hypertension liver cirrhosis Not treat PAHspecific pulmonary medication within 14 day Screening ( Visit 0 ) 6MWD 150 meter 450 meter Patients pregnant Patients currently nitrate and/or nitric oxide ( NO ) donor therapy ; patient currently take phosphodiesterase 5 ( PDE5 ) inhibitor ( sildenafil , tadalafil , vardenafil ) nonspecific PDE inhibitor ( theophylline , dipyridamole ) NonWHO group 1 Pulmonary Hypertension Severe restrictive lung disease History uncontrolled high blood pressure hypotension A medical disorder , condition , history opinion Investigator would impair ability participate complete study Active state hemoptysis pulmonary hemorrhage , include event manage bronchial artery embolization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary Hypertension , Riociguat , Living Pulmonary Hypertension Questionnaire</keyword>
</DOC>